Cat.#: ASSD-138
Description | A3AR covalent antagonist.Binds irreversibly. Apparent pKi values at A3ARs are 6.9 and 8.0 (after 4h), where a Ki shift indicates a covalent mode of action. |
Size | 50 μg |
Chemical Name | 4-[3-(8-Methoxy-2,4-dioxo-3-propylpurino[7,8-a]pyridin-1-yl)propylcarbamoyl]benzenesulfonyl fluoride |
Molecule Weight | 517.5 |
Molecular formula | C23H24FN5O6S |
PubChem identifier | 155513958 |
Purity | >95% |
Solubility | Soluble in DMSO |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-101 | Cresyl Violet Solution (1%) (AC101) | 250 mL, 500 mL, | inquiry |
ASSD-211 | 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester (AC211) | 100 mg, 1 g | inquiry |
ASSD-220 | Nitrofluorescein, Isomer 2 (AC220) | 1 g | inquiry |
ASSD-136 | LUF7445/A2A antagonist (AC136) | 50 μg | inquiry |
ASSD-204 | 7-Diethylamino-3-[N-(2-maleimidoethyl)carbamoyl]coumarin (AC204) | 1 mg, 5 mg | inquiry |
ASSD-152 | Biocytin (AC152) | 10 mg, 50 mg | inquiry |
ASSD-179 | 8-Azidoadenosine-5′-diphosphate Sodium Salt (AC179) | 1 mg, 5 mg | inquiry |
ASSD-198 | NHS-5(6)Carboxyrhodamine (AC198) | 25 mg | inquiry |
ASSD-120 | Fluorescent adenosine antagonist [XAC] (AC120) | 500 μg | inquiry |
ASSD-103 | DAPI Staining Solution (1mg/mL) (AC103) | 1 mL, 5 mL, | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.